
|Articles|July 9, 2019
Tufts: Growth in Rare Disease R&D Challenging Development Strategy and Execution
Advertisement
According to a recently completed analysis from the Tufts Center for the Study of Drug Development, drug development for rare diseases presents scientific and operational challenges that will accelerate the adoption of new development strategies and operating models.
For more on their findings, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Novo Nordisk’s Phase III OASIS 4 Analyses Highlight Cardiometabolic Benefits of Oral Semaglutide 25 mg
2
Using AI and Tokenized Data to Match Patients to Protocols
3
Eli Lilly’s Phase II Trial of Eloralintide Shows Up to 20% Weight Reduction in Adults With Obesity
4
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
5





.png)



.png)



.png)
.png)
